Empagliflozin is a novel, potent and selective sodium glucose co-transporter-2 (SGLT-2) inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Blocking SGLT-2 reduces blood glucose by blocking glucose reabsorption in the kidney and thereby excreting glucose (i.e., blood sugar) via the urine.CAS Number:864070-44-0Molecular Formula:C23H27ClO7